Insights

TLV lowers rebate forecast for confidential agreements

**TLV has lowered its forecast for rebates from confidential agreements.**

The Swedish Dental and Pharmaceutical Benefits Agency (**TLV**) has revised down its forecast for rebates paid under agreements between regions and pharmaceutical companies for 2026–2029.

The main reasons are:
– Slower-than-expected sales growth for certain medicines covered by agreements, particularly medicines added in late 2025 and the first half of 2026.
– List-price reductions for certain medicines.

TLV now forecasts rebates of just over **SEK 4.7 billion** for 2026, a **6.4%** reduction from its June 2026 forecast. Rebates are forecast to rise to SEK 5.1 billion in 2027 and SEK 5.6 billion in 2028.

Eight medicines with agreements have been added since the June forecast. The report also provides a regional allocation of projected rebates for 2026 and 2027.

Since 2024, the state’s share of rebates has been deducted from the annual state contribution to regions, meaning regions receive a net contribution during the year while retaining all rebates received within the contribution year.

Read more at https://www.tlv.se/press/nyheter/arkiv/2026-11-16-tlv-sanker-prognosen-for-aterbaring-fran-sidooverenskommelser.html

Explore cutting-edge insights on optimizing health economics and market access